NUFORMIX PLC

Board/Management Information • Sep 10, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7810L

Nuformix PLC

10 September 2019

10th September 2019

Nuformix plc

("Nuformix" or "the Group"),

Resignation of Kirk Siderman-Wolter

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of Kirk Siderman-Wolter from the Nuformix Board of Directors with immediate effect. The resolution to re-elect Kirk Siderman-Wolter as a Director of the Company at the Annual General Meeting to be held at 1pm today will now be withdrawn from the meeting.

Dr Dan Gooding, CEO, Nuformix plc, said: "On behalf of the Board and the Company, I would like to thank Kirk for his work and commitment to the Board and the Company during his tenure, a period of tremendous growth and change for the Company. The Board would like to wish Kirk well in his future endeavours."

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

Nuformix plc Dr Dan Gooding, Chief Executive Officer	+44 (0)1223 627222
Optimum Strategic Communications Mary Clark, Supriya Mathur Email: nuformix@optimumcomms.com	+44 (0) 20 3950 9144

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix's IP portfolio of granted patents covers cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOALMMATMBIBMFL